Research ArticleCancer

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

See allHide authors and affiliations

Science Translational Medicine  23 Oct 2013:
Vol. 5, Issue 208, pp. 208ra147
DOI: 10.1126/scitranslmed.3006941

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Combating Mesothelioma by Suppressing Friendly Fire

Immunotoxins, which combine a bacterial toxin with an antibody fragment that recognizes a specific protein, offer a way to selectively target and kill cancer cells. Unfortunately, the patient’s immune system usually attacks the immunotoxin as a foreign protein, destroying it before it can reach its target and deliver the toxin to the tumor. Now, Hassan and coauthors have demonstrated a combination treatment approach for preventing the formation of antitoxin antibodies in mesothelioma patients.

Mesothelioma is an aggressive tumor of the pleural and peritoneal membranes, which normally has a poor prognosis and very limited treatment options. SS1P is an immunotoxin targeting mesothelin, a protein that is only found in the mesothelial membranes and highly expressed in mesothelioma. In past clinical trials, the vast majority of treated patients developed antibodies against SS1P after only one cycle of treatment, precluding its continued use as a therapeutic agent. To overcome this problem, Hassan et al. treated chemotherapy-resistant mesothelioma patients with pentostatin and cyclophosphamide, chemotherapeutic agents that specifically deplete lymphocytes and can therefore prevent the formation of antitoxin antibodies, before giving SS1P to the patients. This treatment combination greatly delayed antibody formation, allowing the patients to receive multiple cycles of SS1P, which resulted in improved clinical outcomes.

Future work will be needed to further prolong the presence of this immunotoxin because most patients in the current trial eventually developed antibodies against SS1P. Additional work will also be necessary to clarify the mechanism of the combination treatment and determine whether the immunomodulatory drugs contribute any direct antitumor effects. Nevertheless, the results presented by Hassan and coauthors provide a promising approach for treating an aggressive and deadly tumor, and demonstrate a clever way to overcome immune rejection of immunotoxin treatment.

View Full Text